BEL512 / Belenos Biosciences, Keymed Biosciences - LARVOL DELTA

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. (clinicaltrials.gov) - P2 | N=246 | Recruiting | Sponsor: Keymed Biosciences Co.Ltd

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Belenos Pipeline Updates: First Clinical Data from Lead Asset BEL512, a Long-lasting Bispecific Targeting TSLP and IL-13... (Businesswire) - "The Phase 1b testing two doses (300 mg and 600 mg) of BEL512 vs placebo highlighted significant and durable responses: EASI 75 300 mg group at week 6 of 50% vs 7% in placebo groups; EASI 75 300 mg group at week 12 of 58% vs 21.4% in placebo groups; EASI 90 300 mg group at week 12 of 41.7% vs 0% in placebo groups; These improvements were sustained through to week 24, 20 weeks after the last dose of ‘512. Both serum TSLP and IL-13 rapidly decreased after initial dose, reaching levels below the lower limit of quantification. TARC, eotaxin-3, CCL13, and IgE decreased after the first dose, and reductions were sustained through the 24 week study."

P1 data • Atopic Dermatitis

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis (clinicaltrials.gov) - P1 | N=110 | Completed | Sponsor: Keymed Biosciences Co.Ltd | Not yet recruiting ➔ Completed | Trial completion date: Sep 2026 ➔ Sep 2025 | Trial primary completion date: Sep 2026 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: Keymed Biosciences Co.Ltd

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology